Loading clinical trials...

To Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection | Clinical Trials | Clareo Health

COMPLETEDNA

To Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection

A Prospective Case-control Study to Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-infection - a PET Study

NCT00959166•Imperial College London

View on ClinicalTrials.gov

Summary

This study plans to evaluate what happens to the brain in patients with HIV and early hepatitis C. The investigators will be comparing 3 groups of individuals: * Group 1: Individuals with HIV infection and acute (early) hepatitis C infection * Group 2: Individuals with HIV infection * Group 3: Healthy volunteers

Detailed Description

Subtle changes to the brain, which doctors find difficult to detect through conversation or examination, may occur in patients with HIV and/or hepatitis C infection. It is not currently known whether the brain is affected in early (or acute) hepatitis C. Individuals wishing to take part will complete a series of tests assessing different aspects of their brain including: * 2 brain scans using different technology: * Magnetic resonance imaging (MRI) brain scan with spectroscopy * CT PET brain scan * A computer game test which measures brain function * 2 short questionnaires Results of these tests will be analyzed and compared between 3 groups.

Eligibility

Age

25 - No limit years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•1. HIV-1 antibody positive for at least 12 months
•2. Acute HCV (Blood HCV PCR positive with negative PCR within past 8 months)
•3. HCV genotype 1
•4. Ability to give informed consent
•5. Aged \> 25 years
•6. Male
•7. Abbreviated Mental Test Score of at least 8/10

Exclusion Criteria

•1. Evidence of established cirrhosis or encephalopathy
•2. Commencing or any change to HIV medications within 12 weeks
•3. Active opportunistic infection
•4. Taking anti-depressants or any psychoactive medications within past 4 weeks
•5. Use of benzodiazepines within past 4 weeks
•6. Recent significant head injury
•7. Established dementia
•8. Alcohol dependence or recreational drug misuse
•9. Untreated early syphilis
•10. Hepatitis B infection (HBsAg positive)
+3 more criteria

Locations (1)

St Mary's Hospital

London, United Kingdom

Key Dates

Start Date

June 1, 2009

Primary Completion Date

June 1, 2011

Completion Date

September 1, 2011

Last Updated

October 22, 2019

Enrollment

ACTUAL participants

Conditions

Acute Hepatitis CHIVHIV Infections

Interventions

PET scan

OTHER

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

NCT07071623

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis

View study

RECRUITING

Thinking and Memory Problems in People With HIV

NCT01875588

HIV Positive

View study

RECRUITINGPHASE2

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 22, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

To Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection

Inclusion Criteria

Exclusion Criteria

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Thinking and Memory Problems in People With HIV

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption